AU2003230899A1 - Compositions containing piperacillin and tazobactam useful for injection - Google Patents

Compositions containing piperacillin and tazobactam useful for injection

Info

Publication number
AU2003230899A1
AU2003230899A1 AU2003230899A AU2003230899A AU2003230899A1 AU 2003230899 A1 AU2003230899 A1 AU 2003230899A1 AU 2003230899 A AU2003230899 A AU 2003230899A AU 2003230899 A AU2003230899 A AU 2003230899A AU 2003230899 A1 AU2003230899 A1 AU 2003230899A1
Authority
AU
Australia
Prior art keywords
injection
compositions containing
tazobactam
useful
containing piperacillin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003230899A
Inventor
Jonathan Marc Cohen
Mahdi Bakir Fawzi
Christian Luther Ofslager
Syed Muzafar Shah
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth Holdings LLC
Original Assignee
Wyeth Holdings LLC
Wyeth LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Holdings LLC, Wyeth LLC filed Critical Wyeth Holdings LLC
Publication of AU2003230899A1 publication Critical patent/AU2003230899A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2003230899A 2003-04-14 2003-04-14 Compositions containing piperacillin and tazobactam useful for injection Abandoned AU2003230899A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2003/011340 WO2004098643A1 (en) 2003-04-14 2003-04-14 Compositions containing piperacillin and tazobactam useful for injection

Publications (1)

Publication Number Publication Date
AU2003230899A1 true AU2003230899A1 (en) 2004-11-26

Family

ID=33434315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003230899A Abandoned AU2003230899A1 (en) 2003-04-14 2003-04-14 Compositions containing piperacillin and tazobactam useful for injection

Country Status (2)

Country Link
AU (1) AU2003230899A1 (en)
WO (1) WO2004098643A1 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5591434B2 (en) 2002-12-20 2014-09-17 ゼリス ファーマシューティカルズ インコーポレイテッド Intradermal injection method
DK1468697T3 (en) * 2003-04-14 2008-04-14 Wyeth Corp Compositions containing piperacillin and tazobactam useful for injection
EP1711178A1 (en) * 2004-01-30 2006-10-18 Wyeth Compositions substantially free of galactomannan containing piperacillin and tazobactam
EP1799209A1 (en) * 2004-10-14 2007-06-27 Wyeth Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent
ITMI20051630A1 (en) * 2005-09-02 2007-03-03 Acs Dobfar Spa INJECTABLE STERILE PHARMACEUTICAL FORMULATION CONTAINING AT LEAST TWO ACTIVE PRINCIPLES
ITMI20070568A1 (en) * 2007-03-22 2008-09-23 Acs Dobfar Spa INJECTABLE STERILE PHARMACEUTICAL COMOSIATION HAVING PIPERACILLIN SODIUM AND TAZOBACTAM SODIUM AS ACTIVE PRINCIPLES
CN102018713B (en) * 2009-09-11 2013-01-23 北京四环新盛医药科技有限公司 Medicinal composition
US20120046225A1 (en) 2010-07-19 2012-02-23 The Regents Of The University Of Colorado, A Body Corporate Stable glucagon formulations for the treatment of hypoglycemia
AU2012225268B2 (en) 2011-03-10 2016-10-20 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of peptide drugs
US9138479B2 (en) 2011-10-31 2015-09-22 Xeris Pharmaceuticals, Inc. Formulations for the treatment of diabetes
CN102716435B (en) * 2012-05-05 2013-08-14 周士菊 Traditional Chinese medicine feet-soaking preparation for treating diabetic foot
US9125805B2 (en) 2012-06-27 2015-09-08 Xeris Pharmaceuticals, Inc. Stable formulations for parenteral injection of small molecule drugs
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
US9018162B2 (en) 2013-02-06 2015-04-28 Xeris Pharmaceuticals, Inc. Methods for rapidly treating severe hypoglycemia
US20140274993A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane-tazobactam pharmaceutical compositions
EP3100732A1 (en) 2013-03-15 2016-12-07 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US10376496B2 (en) 2013-09-09 2019-08-13 Merck, Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US8906898B1 (en) 2013-09-27 2014-12-09 Calixa Therapeutics, Inc. Solid forms of ceftolozane
WO2016022831A1 (en) 2014-08-06 2016-02-11 Xeris Pharmaceuticals, Inc. Syringes, kits, and methods for intracutaneous and/or subcutaneous injection of pastes
US9649364B2 (en) 2015-09-25 2017-05-16 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic formulations in aprotic polar solvents
US11590205B2 (en) 2015-09-25 2023-02-28 Xeris Pharmaceuticals, Inc. Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents
WO2018025248A1 (en) * 2016-08-05 2018-02-08 Jodas Expoim Private Limited Edta injection and process for making the same
AU2018275686B2 (en) 2017-06-02 2024-02-01 Xeris Pharmaceuticals, Inc. Precipitation resistant small molecule drug formulations
CN112618486B (en) * 2020-12-24 2023-07-18 浙江昂利康制药股份有限公司 Suspension oil for injection and preparation method thereof
CN115554298A (en) * 2021-07-01 2023-01-03 北京诺康达医药科技股份有限公司 Tazobactam and piperacillin combined preparation and preparation method thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503881B2 (en) * 1996-08-21 2003-01-07 Micrologix Biotech Inc. Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics
US6207661B1 (en) * 1999-02-22 2001-03-27 Baxter International Inc. Premixed formulation of piperacillin sodium and tazobactam sodium injection
AU2003225073A1 (en) * 2002-04-18 2003-11-03 The University Of Iowa Research Foundation Methods of inhibiting and treating bacterial biofilms by metal chelators

Also Published As

Publication number Publication date
WO2004098643A1 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
GB2400557B (en) Compositions containing piperacillin and tazobactam useful for injection
AU2003230899A1 (en) Compositions containing piperacillin and tazobactam useful for injection
IL173639A0 (en) Ppar-activating compound and pharmaceutical composition containing same
AU2003220205A1 (en) Ethanol-diesel fuel composition and methods thereof
EP1518918A2 (en) Fuels compositions and methods for using same
AU2003251429A1 (en) Cosmetic compositions and container therefor
AU2003298514A1 (en) Methods and compositions using cholinesterase inhibitors
AU2003267644A1 (en) Dental compositions and methods
IL197889A (en) Pyridylvinylazacyclopentane compound and pharmaceutical compositions comprising same
AU2002212739A1 (en) Compositions for forming bone or periodontium and injections for forming bone orperiodontium
AU2003256805A1 (en) Compounds compositions and methods
AU2001292185A1 (en) Formulation containing amoxicillin
AU2003239867A1 (en) Sunscreen compositions and containing azolium compounds
AU2003291443A1 (en) Compositions and processes for nanoimprinting
AU2003261053A1 (en) Fuel additive composition and its preparation
AU2001292047A1 (en) Composition containing an azaphthalocyanine and use
AU2003272896A1 (en) Valerolactone compounds and perfume composition
AU2003287249A1 (en) Organic acid containing compositions and methods for use thereof
AU2003252683A1 (en) Composition for oral use
EP1541139A4 (en) Drug composition containing nf-kappa b inhibitor
EP1572950A3 (en) Single domain tdf-related compounds and analogs thereof
AU2003252493A1 (en) Pharmaceutical composition containing decoy and method of using the same
AU2003222058A1 (en) Materials and methods for inhibiting wip-1
AU2003298810A1 (en) NF-kB INHIBITORS AND USES THEREOF
AU2003283727A1 (en) Recording start and stop

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase